Alnylam Pharmaceuticals ALNY
$143.82 −$4.00 (-2.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $144.50 +0.47%
Open$148.35
Prev close$147.82
Day range$143.40 – $151.41
Volume2.33M
Market cap$19.26B
P/E (TTM)7.5
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$1.46B+16.7% YoY
Operating profit$345.80M-6.0% YoY
Net profit$2.17B+640.5% YoY
Diluted EPS$15.72+634.6% YoY
Free cash flow$271.15M-4.8% YoY
Operating cash flow$340.99M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin77.3%
Operating margin19.5%
Net margin52.8%
Return on equity138.1%
Return on assets41.2%
Return on invested capital86.2%
Current ratio2.48
Liabilities / assets54.9%
Cash & investments$3.59B
Total debt$1.22B
Net cash (debt)$2.37B
Free cash flow / sales16.1%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $1.46B | $1.29B | $1.17B | $3.71B | $1.10B |
| Total Operating Revenue | $1.46B | $1.29B | $1.17B | $3.71B | $1.10B |
| Cost of Revenue | $361.75M | $298.45M | $211.12M | $681.87M | $267.72M |
| Gross Profit | $1.10B | $992.50M | $956.05M | $3.03B | $829.31M |
| Operating Expense | $750.54M | $761.06M | $687.42M | $2.53B | $697.59M |
| Selling and Admin Expenses | $342.00M | $347.92M | $322.55M | $1.21B | $325.37M |
| -General & Admin Expense | $342.00M | $347.92M | $322.55M | $1.21B | $325.37M |
| Research & Development | $408.54M | $413.13M | $364.87M | $1.32B | $372.22M |
| Operating Profit | $345.80M | $231.44M | $268.64M | $501.58M | $131.72M |
| Net Non-Operating Interest Income (Expense) | -$53.43M | -$53.91M | -$42.69M | -$141.16M | -$38.77M |
| Non-Operating Interest Income | $30.94M | $28.14M | $26.60M | $111.47M | $26.63M |
| Non-Operating Interest Expense | $84.37M | $82.05M | $69.29M | $252.63M | $65.40M |
| Other Income (Expense) | $3.44M | $273,000.00 | -$4.30M | -$37.27M | -$6.69M |
| Special Income (Charges) | $0.00 | – | – | -$42.47M | -$3.33M |
| Other Non-Operating Income (Expenses) | $3.44M | $273,000.00 | -$4.30M | $7.51M | -$1.05M |
| Pretax Profit | $295.81M | $177.81M | $221.65M | $323.15M | $86.26M |
| Tax | -$1.87B | $13.31M | $15.66M | $9.41M | -$25.28M |
| Net Profit | $2.17B | $164.49M | $205.99M | $313.75M | $111.54M |
| Profit from Continuing Operations | $2.17B | $164.49M | $205.99M | $313.75M | $111.54M |
| Net Income to Parent Company | $2.17B | $164.49M | $205.99M | $313.75M | $111.54M |
| Net Income to Common Stockholders | $2.17B | $164.49M | $205.99M | $313.75M | $111.54M |
| Basic EPS | $16.19 | $1.23 | $1.55 | $2.39 | $0.84 |
| Diluted EPS | $15.72 | $1.21 | $1.51 | $2.33 | $0.82 |
| Gain on Sale of Security | – | – | – | -$2.31M | $138.81M |
| -Less:Other Special Charges | – | – | – | $42.47M | $3.33M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $7.99B | $5.56B | $5.13B | $4.97B | $4.97B |
| Total Current Assets | $5.11B | $4.62B | $4.22B | $4.05B | $4.05B |
| Cash and Cash Equivalents & Short-Term Investments | $3.59B | $3.31B | $3.01B | $2.91B | $2.91B |
| -Cash and Cash Equivalents | $1.75B | $1.71B | $1.71B | $1.66B | $1.66B |
| -Short Term Investments | $1.83B | $1.60B | $1.30B | $1.25B | $1.25B |
| Receivables | $1.08B | $912.74M | $883.96M | $777.57M | $777.57M |
| -Accounts Receivable | $1.08B | $912.74M | $883.96M | $777.57M | $777.57M |
| Inventory | $105.91M | $97.11M | $84.03M | $82.72M | $82.72M |
| Other Current Assets | $334.60M | $302.18M | $242.10M | $281.89M | $281.89M |
| Total Non-Current Assets | $2.88B | $938.60M | $910.24M | $915.67M | $915.67M |
| Net PPE | $792.86M | $737.50M | $707.56M | $708.06M | $708.06M |
| -Gross PPE | $792.86M | $737.50M | $707.56M | $1.03B | $1.03B |
| Non-Current Deferred Assets | $2.01B | $113.79M | $116.96M | $125.98M | $125.98M |
| Other Non-Current Assets | $82.48M | $87.30M | $85.72M | $81.63M | $81.63M |
| Total Liabilities | $4.39B | $4.20B | $4.05B | $4.18B | $4.18B |
| Total Current Liabilities | $2.06B | $1.51B | $1.35B | $1.47B | $1.47B |
| Payables | $135.40M | $108.02M | $126.63M | $115.72M | $115.72M |
| -Accounts Payable | $135.40M | $108.02M | $126.63M | $115.72M | $115.72M |
| Current Accrued Expenses | $1.24B | $1.10B | $946.49M | $823.00M | $823.00M |
| Short-Term Debt and Capital Lease Obligation | $407.61M | $45.93M | $45.66M | $45.52M | $45.52M |
| -Current Debt | $361.53M | – | – | – | – |
| -Current Capital Lease Obligation | $46.08M | $45.93M | $45.66M | $45.52M | $45.52M |
| Current Deferred Liabilities | $11.67M | $4.01M | $3.21M | $4.85M | $4.85M |
| Other Current Liabilities | $272.04M | $258.57M | $227.49M | $220.07M | $220.07M |
| Total Non-Current Liabilities | $2.33B | $2.69B | $2.70B | $2.71B | $2.71B |
| Long Term Debt and Capital Lease Obligation | $854.38M | $1.22B | $1.23B | $1.23B | $1.23B |
| -Long Term Debt | $651.09M | $1.01B | $1.01B | $1.01B | $1.01B |
| -Long Term Capital Lease Obligation | $203.29M | $210.50M | $218.03M | $225.09M | $225.09M |
| Other Non-Current Liabilities | $1.47B | $1.47B | $1.48B | $1.48B | $1.48B |
| Total Equity | $3.60B | $1.35B | $1.08B | $789.18M | $789.18M |
| Stockholders' Equity | $3.60B | $1.35B | $1.08B | $789.18M | $789.18M |
| Capital Stock | $1.34M | $1.34M | $1.33M | $1.32M | $1.32M |
| -Common Stock | $1.34M | $1.34M | $1.33M | $1.32M | $1.32M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $7.81B | $7.72B | $7.60B | $7.51B | $7.51B |
| Retained Earnings | -$4.16B | -$6.33B | -$6.50B | -$6.70B | -$6.70B |
| Gains/Losses Not Affecting Retained Earnings | -$44.66M | -$32.14M | -$24.89M | -$20.10M | -$20.10M |
| -Accumulated Depreciation | – | – | – | -$322.70M | -$322.70M |
| Derivative Product Liabilities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $340.99M | $326.72M | $70.50M | $524.08M | $217.73M |
| Net cash flow from continuing operations | $340.99M | $326.72M | $70.50M | $524.08M | $217.73M |
| Net Income from Continuing Operations | $2.17B | $164.49M | $205.99M | $313.75M | $111.54M |
| Depreciation & Depletion & Amortization | $14.48M | $13.90M | $13.55M | $55.66M | $13.51M |
| Deferred Tax | -$1.89B | $2.66M | $9.31M | -$2.20M | -$27.17M |
| Other Non-Cash Items | $77.94M | $87.32M | $69.23M | $251.11M | $106.34M |
| Change in Working Capital | -$103.15M | -$28.27M | -$297.73M | -$444.78M | -$18.98M |
| -Change in Receivables | -$171.28M | -$31.60M | -$110.42M | -$359.96M | $184.25M |
| -Change in Inventory | $913,000.00 | $280,000.00 | -$3.32M | $8.47M | -$13.86M |
| -Change in Prepaid Assets | -$36.41M | -$59.37M | -$6.32M | -$117.72M | -$70.99M |
| -Change in Payables and Accrued Expense | $95.96M | $61.62M | -$176.03M | $75.07M | -$120.68M |
| -Change In Other Working Capital | $7.66M | $802,000.00 | -$1.63M | -$50.64M | $2.31M |
| Net cash flow from investing | -$311.74M | -$363.46M | -$25.54M | $436.33M | -$37.17M |
| Net Cash Flow from Continuing Investing Activities | -$311.74M | -$363.46M | -$25.54M | $436.33M | -$37.17M |
| Net PPE Purchase and Sale | -$69.83M | -$34.68M | -$21.83M | -$58.70M | -$23.29M |
| Net Investment Purchase and Sale | -$242.41M | -$302.88M | -$48.43M | $497.18M | -$13.87M |
| Net Other Investing Changes | $500,000.00 | -$25.90M | $44.73M | -$2.15M | $0.00 |
| Financing Cash Flow | $18.35M | $36.24M | $15.71M | -$305.19M | -$8.86M |
| Net Cash Flow from Continuing Financing Activities | $18.35M | $36.24M | $15.71M | -$305.19M | -$8.86M |
| Proceeds from Stock Option Exercised | $15.47M | $33.56M | $13.16M | $250.03M | $41.70M |
| Net Other Financing Charges | $12.75M | $2.68M | $2.56M | -$10.69M | -$8.27M |
| Ending Cash Balance | $1.76B | $1.71B | $1.71B | $1.66B | $1.66B |
| Net Change in Cash | $47.60M | -$496,000.00 | $60.68M | $655.22M | $171.71M |
| Beginning Cash Balance | $1.71B | $1.71B | $1.66B | $968.65M | $1.49B |
| Effect of Exchange Rate Changes | -$1.26M | -$2.45M | -$7.06M | $34.94M | -$5.70M |
| Free Cash Flow | $271.15M | $292.04M | $48.67M | $465.38M | $194.44M |
| Gain/Loss from Continuing Operations | – | – | – | $2.31M | -$39.15M |
| Net Issuance Payments Of Debt | – | – | – | -$544.53M | -$42.29M |
No comments yet — be the first to weigh in on ALNY.
Sign in to join the discussion.